Krystal Biotech to Present at ARVO 2024 Annual Meeting

Krystal Biotech, Inc., a commercial-stage biotechnology company listed on NASDAQ under the symbol KRYS, has announced its participation in the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting. The meeting will take place from May 5-9, 2024, in Seattle, Washington. The company plans to present new preclinical data showcasing the potential of its HSV-1 based vector platform for gene delivery to the back of the eye.

The poster presentation will be delivered by Haley Nicole Cartwright on May 7, 2024, between 3:30 PM and 5:15 PM PT. The specific details for the presentation are as follows: Posterboard Number B0022 and Abstract Number 3978 - B0022. Conference attendees will have access to the poster, and it will also be available online in the Investor section of Krystal Biotech's website after the presentation.

Based in Pittsburgh, Pennsylvania, Krystal Biotech focuses on discovering, developing, and commercializing genetic medicines aimed at treating diseases with significant unmet medical needs. The company has launched VYJUVEK®, the first-ever redosable gene therapy and the first FDA-approved treatment for dystrophic epidermolysis bullosa. Krystal Biotech is also progressing a robust pipeline of preclinical and clinical investigational genetic medicines in various fields, including respiratory, oncology, dermatology, ophthalmology, and aesthetics.